KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Adaptive Biotechnologies (ADPT) Research & Development (2018 - 2025)

Adaptive Biotechnologies' Research & Development history spans 8 years, with the latest figure at $21.8 million for Q4 2025.

  • For Q4 2025, Research & Development fell 6.16% year-over-year to $21.8 million; the TTM value through Dec 2025 reached $93.8 million, down 8.92%, while the annual FY2025 figure was $93.8 million, 8.92% down from the prior year.
  • Research & Development for Q4 2025 was $21.8 million at Adaptive Biotechnologies, down from $23.7 million in the prior quarter.
  • Across five years, Research & Development topped out at $37.8 million in Q1 2022 and bottomed at $21.8 million in Q4 2025.
  • The 5-year median for Research & Development is $30.7 million (2022), against an average of $30.1 million.
  • The largest annual shift saw Research & Development skyrocketed 45.43% in 2021 before it decreased 21.35% in 2024.
  • A 5-year view of Research & Development shows it stood at $34.7 million in 2021, then decreased by 10.02% to $31.2 million in 2022, then dropped by 7.93% to $28.7 million in 2023, then decreased by 19.32% to $23.2 million in 2024, then decreased by 6.16% to $21.8 million in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Research & Development are $21.8 million (Q4 2025), $23.7 million (Q3 2025), and $24.1 million (Q2 2025).